Methods for treating cancers and restenosis with P21
US5863904A · kind A · utility
29Cited by
0References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 26, 1995 |
| Grant date | Jan 26, 1999 |
| Priority date | — |
| Expiry date | Sep 26, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K48/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The p21 gene encodes a cyclin dependent kinase inhibitor which affects cell cycle progression, but the role of this gene product in altering tumor growth has not been established. The present inventors have now discovered that the growth of malignant cells in vivo is inhibited by expression of p21. Expression of p21 resulted in an accumulation of cells in G.sub.0 /G.sub.1, alteration in morphology, and cell differentiation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.